Intrahepatic Cholangiocarcinoma Cell Line (LD-1)
LD-1 is a Yap and AKT derived murine cholangiocarcinoma cell line.
Highlights:
- Useful for the study of biology and treatment of cholangiocarcinoma
- Express CK-7 and CK-19
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts inside the liver. Risk factors for cholangiocarcinoma include primary sclerosing cholangitis (PSC), ulcerative colitis, cirrhosis, hepatitis C, hepatitis B, infection with certain liver flukes, and some congenital liver malformations.
From the laboratory of Tim F. Greten, MD, National Cancer Institute/NIH.
LD-1 is a Yap and AKT derived murine cholangiocarcinoma cell line.
Highlights:
- Useful for the study of biology and treatment of cholangiocarcinoma
- Express CK-7 and CK-19
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts inside the liver. Risk factors for cholangiocarcinoma include primary sclerosing cholangitis (PSC), ulcerative colitis, cirrhosis, hepatitis C, hepatitis B, infection with certain liver flukes, and some congenital liver malformations.
From the laboratory of Tim F. Greten, MD, National Cancer Institute/NIH.
This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.
Specifications
| Product Type: | Cell Line |
| Name: | LD-1 |
| Cell Type: | Intrahepatic cholangiocarcinoma |
| Accession ID: | CVCL_C7SL |
| Source: | Liver |
| Organism: | C57BL6 mouse |
| Biosafety Level: | BSL-2 |
| Subculturing: | Split 1:5 to 1:10 every 3 days |
| Growth Conditions: | RPMI glutamax with 10% FCS and 1% P/S |
| Cryopreservation: | FCS + 10% DMSO |
| Comments: | LD1 cholangiocarcinoma cell line in C57BL/6 background was established in our lab and is derived from a mouse after hydrodynamic injection with AKT and YAP plasmids. The sequencing data of LD1 was uploaded as SRA submission SUB8582522, BioProject accession PRJNA679802. |
| Storage: | LN2 |
| Shipped: | Dry ice |
Provider
From the laboratory of Tim F. Greten, MD, National Cancer Institute/NIH.
References
- Wabitsch S, Tandon M, Ruf B, Zhang Q, McCallen JD, McVey JC, Ma C, Green BL, Diggs LP, Heinrich B, Greten TF. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cell Mol Gastroenterol Hepatol. 2021;12(3):1166-1178. doi: 10.1016/j.jcmgh.2021.05.011. Epub 2021 May 23. PMID: 34033968; PMCID: PMC8413239.
- Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown ZJ, Wabitsch S, Thovarai V, Fu J, Feng D, Ruf B, Cui LL, Subramanyam V, Frank KM, Wang S, Kleiner DE, Ritz T, Rupp C, Gao B, Longerich T, Kroemer A, Wang XW, Ruchirawat M, Korangy F, Schnabl B, Trinchieri G, Greten TF. Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discov. 2021 May;11(5):1248-1267. doi: 10.1158/2159-8290.CD-20-0304. Epub 2020 Dec 15. PMID: 33323397; PMCID: PMC8102309.
If you publish research with this product, please let us know so we can cite your paper.
